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 Patent ductus arteriosus (PDA) may contribute a 
left-to-right shunt through the ductus and aggra-
vate the respiratory and circulatory problems in 
premature or full-term neonates. It has been esti-
mated that PDA can be demonstrated in 80% of pre-
term infants weighing less than 750 g at the age of 
3 days. 1,2 When spontaneous closure does not occur, 
indomethacin, a cyclooxygenase inhibitor, is used 
to effectively close the patent ductus particularly 
in premature newborns. 1−4 In premature babies, 
the ductus arteriosus contraction after birth is de-
layed mainly due to the immature prostaglandin 
metabolism, high reactivity to prostaglandin, and 
reduced calcium sensitivity to oxygen of the vas-
cular smooth muscle cells in the immature lung. 1 
These also account for the mechanisms responsi-
ble for the indomethacin closure of the PDA in pre-
mature babies. 1,4—6  However, in full-term newborns, 
although physiological closure of the ductus often 
occurs around the age of 3 days, some coexisting dis-
ease conditions may delay the physiological constric-
tion of the ductal tissue. 1,4 The left-to-right shunt 
may further aggravate the circulatory or pulmonary 
problems. Thus, the point at which PDA becomes 
significant and needs to be actively managed is an 
important issue in perinatal medicine. 
 In the current issue of the Journal, Lin et al 7 re-
ported their experience with 44 full-term or near-
term babies born between 2004 and 2006 and were 
symptomatic due to a PDA. They classified the ne-
onates according to their PDA treatment regimens, 
and found that about 14% of the patients spontane-
ously improved within a week. For those requiring fur-
ther medications, including inotropic agents, diuretics 
and indomethacin treatment, or surgical ligation, the 
left atrium to aortic root (LA/Ao) ratio was more 
likely to be larger while the body weight tended to 
be smaller. However, the differences in gestational 
age were unremarkable. With regard to the role 
played by indomethacin in the management of full 
term PDA, the closure rate (9/15, 60%) was similar 
to those of previous reports,3,5 but lower than that 
of premature babies. Surgical ligation was required 
in about one-third of the patients. The authors also 
addressed the supportive treatment in about one-
third of the patients (including anti-congestive 
medications in about half of these patients), which 
stabilized the patients and alleviated the respira-
tory distress. They concluded that the LA/Ao ratio 
was significantly greater in those requiring ductus 
closure interventions as compared to those receiving 
only medical therapy or support. The mean LA/Ao 
ratio was 1.236 in those requiring ductus closure 
intervention. 
 LA/Ao ratio has been a useful marker for signifi-
cant left-to-right shunt from PDA in preterm babies. 
A ratio > 1.15−1.4 has been used as an effective 
echocardiographic criterion for the diagnosis of PDA 
when only M-mode echocardiographic module was 
available. 8 Using the criterion of 1.15 may increase 
the diagnostic sensitivity, but would likely lower 
the specificity. 8,9 A recent study10 in 23 preterm in-
fants of 24−30 weeks’ gestational age and less than 
48 hours’ postnatal age showed that (1) an LA/Ao 
ratio greater than or equal to 1.4, (2) a PDA diam-
eter greater than or equal to 1.4 mm/kg, and (3) 
mean and end diastolic flow velocities of left pul-
monary artery greater than or equal to 0.42 m/s 
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and 0.20 m/s, respectively, identified a significant 
left-to-right shunt from PDA with a sensitivity and 
a specificity above 90%. 
 Recent studies have also indicated the poten-
tial of applying other biomarkers to predict the se-
verity of PDA. Several studies 11−13 disclosed that 
plasma B-type natriuretic peptide levels after the 
age of two days were significantly higher in pre-
term babies with symptomatic PDA and correlated 
well with the magnitude of shunting through the PDA. 
Similarly, in the study by El-Khuffash and Molloy, 14 
serum levels of cardiac troponin T (cTnT) obtained 
at age 12 and 48 hours were significantly elevated 
in preterm neonates with PDA > 1.5 mm (i.e., those 
requiring treatment). They proposed that ductal steal 
due to left-to-right shunting may impair the flow 
of coronary arteries, causing myocardial ischemia 
and a rise in cTnT level. 
 For neonates with symptomatic PDA that are 
refractory to conventional medical therapy, clo-
sure of the PDA either by surgery or by transcath-
eter occlusion with coils or ductal occluders should 
be considered as definite treatment. Surgical liga-
tion of PDA through a lateral thoracotomy is a sim-
ple and safe procedure with minimal morbidity and 
mortality. Video-assisted thoracoscopic closure was 
recently introduced as an alternative treatment op-
tion with similar efficacy and shorter hospital stay 
comparing with open thoracotomy. 15 Catheter clo-
sure of PDA was previously regarded for infant no 
less than 6 kg because of the difficulties in posi-
tioning the relatively large implant and risks of ob-
struction over the left pulmonary artery or aorta 
in smaller infants. 16 But several recent reports 17,18 
indicated that the ductal occluder could be im-
planted in small infants with moderate to large 
PDA safely and effectively. In addition, a newly de-
signed ductal occluder with smaller introducing 
sheath and two retention discs to avoid emboliza-
tion is now available for clinical use. 19 With the 
evolution of newer occluder devices, transcathe-
ter closure of PDA in neonates may become more 
widely utilized in near future. 
 In summary, for neonates with symptomatic PDA, 
several indicators can provide clues on disease se-
verity and the necessity of more aggressive treat-
ment. These indicators include smaller body weight, 
increased ratio of LA/Ao, larger size of ductus, in-
creased end diastolic flow velocity of left pulmo-
nary artery and elevated biomarkers such as B-type 
natriuretic peptide or cTnT. Although surgical liga-
tion of PDA is currently still regarded as a first-line 
treatment in newborn patients, the development of 
video-assisted thoracoscopic closure or transcathe-
ter occlusion of PDA may provide new treatment op-
tions with less invasiveness and comparable safety. 
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